Market Cap 414.77M
Revenue (ttm) 30.91M
Net Income (ttm) -209.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -677.68%
Debt to Equity Ratio 0.89
Volume 2,201,424
Avg Vol 2,262,798
Day's Range N/A - N/A
Shares Out 87.87M
Stochastic %K 14%
Beta 0.34
Analysts Strong Sell
Price Target $16.25

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small mole...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 292 4200
Address:
117 Kendrick Street, Suite 500, Needham, United States
BioTechChap
BioTechChap May. 15 at 8:46 PM
$VSTM Baker Bro’s initiating with 500k shares in Q1 is a good sign, we’re in good company
1 · Reply
StockWanderer
StockWanderer May. 15 at 8:34 PM
$VSTM I love how all the analyst have this stock at $16 for last few years. Arent they supposed to Be looking at coming year . They out of their mind. It just sucks us in to Holding longer. Analyst should Have this stock at $6-7 not 16. No basis for that wildly optimistic number
0 · Reply
Always_neutral
Always_neutral May. 15 at 8:25 PM
$VSTM Sold at 6 and back at 4.30 in this round. I expect it goes down to 4 on Monday morning before heading back. I could be wrong too but that's how early stage commercial or clinical stage biotechs work, hunting ground for shorts. Good luck to longs. I am confident this will go up again soon.
0 · Reply
Sdcharger
Sdcharger May. 15 at 8:16 PM
$VSTM Smart money, Polar Capital (they have one of the best track records in all of biotech), sold their entire 4 million share stake in the 1Q. Clearly they lost confidence in Dan and the story.
1 · Reply
SagehenNed
SagehenNed May. 15 at 8:06 PM
$VSTM Of note, GenFleet is down 30% off its highs of just 10 days ago. Something is rotten in the state of VSTM.
0 · Reply
Adorno99
Adorno99 May. 15 at 8:03 PM
$VSTM nice short attack. Something must be up!
1 · Reply
PencilNeckGeek
PencilNeckGeek May. 15 at 7:56 PM
$VSTM Epic shit show. Absolutely epic
1 · Reply
SagehenNed
SagehenNed May. 15 at 7:46 PM
$VSTM Gapping down to new lows at the close. Some things never change. We're now off over 30% since reporting earnings last week. Management has been asleep at the switch here, Or they simply don't care about their shareholders.
0 · Reply
CallMeEddieMush
CallMeEddieMush May. 15 at 7:17 PM
$VSTM I guess this shit is really almost over
1 · Reply
TheBestLife
TheBestLife May. 15 at 6:24 PM
$VSTM please go belly up and out us out of our misery.. junk
1 · Reply
Latest News on VSTM
Verastem price target lowered to $14 from $16 at Mizuho

2026-05-14T12:35:05.000Z - 1 day ago

Verastem price target lowered to $14 from $16 at Mizuho


Verastem Oncology to Present at Upcoming Investor Conferences

May 12, 2026, 7:30 AM EDT - 3 days ago

Verastem Oncology to Present at Upcoming Investor Conferences


Verastem price target lowered to $18 from $19 at BTIG

2026-05-08T12:55:59.000Z - 7 days ago

Verastem price target lowered to $18 from $19 at BTIG


Verastem reports Q1 adjusted EPS (43c), consensus (47c)

2026-05-07T21:47:04.000Z - 8 days ago

Verastem reports Q1 adjusted EPS (43c), consensus (47c)


Verastem Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 8 days ago

Verastem Earnings Call Transcript: Q1 2026


Verastem assumed with a Buy at Jefferies

2026-03-30T13:00:48.000Z - 6 weeks ago

Verastem assumed with a Buy at Jefferies


Verastem management to meet with Cantor

2026-03-26T21:06:04.000Z - 7 weeks ago

Verastem management to meet with Cantor


Verastem assumed with a Buy at BTIG

2026-03-11T20:28:30.000Z - 2 months ago

Verastem assumed with a Buy at BTIG


Verastem price target raised to $18 from $16 at Alliance Global

2026-03-05T12:09:05.000Z - 2 months ago

Verastem price target raised to $18 from $16 at Alliance Global


Verastem Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 2 months ago

Verastem Earnings Call Transcript: Q4 2025


Verastem reports Q4 adjusted EPS (48c), consensus (50c)

2026-03-04T21:06:51.000Z - 2 months ago

Verastem reports Q4 adjusted EPS (48c), consensus (50c)


Verastem announces upcoming key milestones

2026-03-04T21:06:00.000Z - 2 months ago

Verastem announces upcoming key milestones


Verastem price target raised to $18 from $15 at Mizuho

2026-02-19T12:27:12.000Z - 3 months ago

Verastem price target raised to $18 from $15 at Mizuho


Verastem assumed with a Buy at H.C. Wainwright

2026-02-04T11:10:47.000Z - 3 months ago

Verastem assumed with a Buy at H.C. Wainwright


Verastem Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 9:30 AM EST - 6 months ago

Verastem Transcript: Jefferies London Healthcare Conference 2025


Verastem Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 6 months ago

Verastem Earnings Call Transcript: Q3 2025


Verastem Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 9 months ago

Verastem Transcript: Cantor Global Healthcare Conference 2025


Verastem Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Verastem Earnings Call Transcript: Q2 2025


Verastem Transcript: R&D Day 2025

Jun 2, 2025, 12:00 PM EDT - 1 year ago

Verastem Transcript: R&D Day 2025


U.S. FDA approves Verastem's cancer therapy

May 8, 2025, 12:23 PM EDT - 1 year ago

U.S. FDA approves Verastem's cancer therapy


Verastem Oncology Announces $75 million Private Placement

Apr 25, 2025, 9:00 AM EDT - 1 year ago

Verastem Oncology Announces $75 million Private Placement


Verastem Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 1:00 PM EST - 1 year ago

Verastem Transcript: Guggenheim SMID Cap Biotech Conference


BioTechChap
BioTechChap May. 15 at 8:46 PM
$VSTM Baker Bro’s initiating with 500k shares in Q1 is a good sign, we’re in good company
1 · Reply
StockWanderer
StockWanderer May. 15 at 8:34 PM
$VSTM I love how all the analyst have this stock at $16 for last few years. Arent they supposed to Be looking at coming year . They out of their mind. It just sucks us in to Holding longer. Analyst should Have this stock at $6-7 not 16. No basis for that wildly optimistic number
0 · Reply
Always_neutral
Always_neutral May. 15 at 8:25 PM
$VSTM Sold at 6 and back at 4.30 in this round. I expect it goes down to 4 on Monday morning before heading back. I could be wrong too but that's how early stage commercial or clinical stage biotechs work, hunting ground for shorts. Good luck to longs. I am confident this will go up again soon.
0 · Reply
Sdcharger
Sdcharger May. 15 at 8:16 PM
$VSTM Smart money, Polar Capital (they have one of the best track records in all of biotech), sold their entire 4 million share stake in the 1Q. Clearly they lost confidence in Dan and the story.
1 · Reply
SagehenNed
SagehenNed May. 15 at 8:06 PM
$VSTM Of note, GenFleet is down 30% off its highs of just 10 days ago. Something is rotten in the state of VSTM.
0 · Reply
Adorno99
Adorno99 May. 15 at 8:03 PM
$VSTM nice short attack. Something must be up!
1 · Reply
PencilNeckGeek
PencilNeckGeek May. 15 at 7:56 PM
$VSTM Epic shit show. Absolutely epic
1 · Reply
SagehenNed
SagehenNed May. 15 at 7:46 PM
$VSTM Gapping down to new lows at the close. Some things never change. We're now off over 30% since reporting earnings last week. Management has been asleep at the switch here, Or they simply don't care about their shareholders.
0 · Reply
CallMeEddieMush
CallMeEddieMush May. 15 at 7:17 PM
$VSTM I guess this shit is really almost over
1 · Reply
TheBestLife
TheBestLife May. 15 at 6:24 PM
$VSTM please go belly up and out us out of our misery.. junk
1 · Reply
sweddle
sweddle May. 15 at 5:47 PM
1 · Reply
PencilNeckGeek
PencilNeckGeek May. 15 at 4:59 PM
$VSTM Don't worry it's only 30% down this month and 20% down this week
2 · Reply
PencilNeckGeek
PencilNeckGeek May. 15 at 4:56 PM
$VSTM Shorts know that partnership interest, CEO keeps blabbing about, is all lies and that dilution is on the way. They have absolutely zero fear at this point
2 · Reply
JohnBiotech
JohnBiotech May. 15 at 4:51 PM
$VSTM good day to buy
0 · Reply
beeelaaal
beeelaaal May. 15 at 4:38 PM
$VSTM institutional buyjng , great data , this thing slips ?
0 · Reply
Aurum81
Aurum81 May. 15 at 4:38 PM
$VSTM RSI sub 30 = oversold
1 · Reply
PencilNeckGeek
PencilNeckGeek May. 15 at 4:35 PM
$VSTM What an epic collapse
0 · Reply
UnlikelyResult
UnlikelyResult May. 15 at 4:16 PM
$VSTM Thanks for introducing us to all the funds funneling shares to the shorts
1 · Reply
Marketismanipulated2
Marketismanipulated2 May. 15 at 4:14 PM
$VSTM Fuck this shit! Where is that POS ceo?🤬🤬🤬
1 · Reply
TwongStocks
TwongStocks May. 15 at 3:17 PM
$VSTM 13G filed by Armsitice. https://www.sec.gov/Archives/edgar/data/1526119/000117266126002132/xslSCHEDULE_13G_X02/primary_doc.xml Reports beneficial ownership of 4,592,000 shares, 5.23%, as of March 31. Unlike BAM or RTW, Armistice did not specify what OS they used to calculate their beneficial ownership. Based on the 5.23% reported, it appears they used the same figures as BAM and RTW --> 87,835,106 shares outstanding as of Feb 27. Armistice previously reported beneficial ownership of 3,536,000 shares as of Dec 31 https://www.sec.gov/Archives/edgar/data/1526119/000117266126001235/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
Marketismanipulated2
Marketismanipulated2 May. 15 at 2:57 PM
$VSTM wish I never bought back into this POS. The CEO is absolutely fucking useless.
0 · Reply
PencilNeckGeek
PencilNeckGeek May. 15 at 2:55 PM
0 · Reply